Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

DZ Bank has significantly reduced its holdings in Regeneron Pharmaceuticals, offloading 74.4% of its shares in Q4. Despite ...

Regeneron’s fund will be independently managed by former Regeneron executives Jay Markowitz and Michael Aberman, said the company, which said the primary interest of the new fund is in ...

Deutsche Bank AG boosted its stake in Regeneron Pharmaceuticals by nearly 22% in Q4, now holding 539,269 shares valued at ...

Alabama‘s Tommy Tuberville trades more stocks than any other member of the U.S. Senate, finding himself on lists of top ...

Quarter ResultsFormycon reports strong operational performance and financial results for first quarter of 2025 12.05.2025 / 06:30 CET/CESTThe issuer is solely responsible for the content of this ...

Shares of Regeneron Pharmaceuticals Inc. REGN advanced 2.39% to $584.99 Thursday, on what proved to be an all-around positive ...

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from ...

Regeneron (REGN) stock was upgraded to Buy and AbbVie (ABBV) stock was downgraded at Citi based on policy risks under Trump's drug reforms. Read more here.

The recent 8.5% decline in Regeneron Pharmaceuticals' share price contrasts with the broader market performance and may reflect investor concerns about near-term hurdles like the FDA's complete ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...